Monday, November 29, 2021 11:09:26 AM
"HOUSE OF PINCHERS" BOARD IS ALIVE
Have you pinched lately?
investorshub.advfn.com/%22House-of-Pinchers%22-9737/
Recent QLGN News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:30:40 PM
- Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 07:16:19 PM
- Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer • GlobeNewswire Inc. • 10/23/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 12:30:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:15:36 PM
- Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 • GlobeNewswire Inc. • 09/27/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:18 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:15:06 PM
- Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 08/17/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2023 02:04:16 PM
- Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 • GlobeNewswire Inc. • 08/15/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:16:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:30:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 12:35:11 PM
- Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 08/01/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2023 09:25:16 PM
- Qualigen Therapeutics Divests FastPack® Diagnostics Business • GlobeNewswire Inc. • 07/24/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 09:29:37 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/07/2023 09:08:22 PM
- Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting • GlobeNewswire Inc. • 06/05/2023 12:15:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM